

Target Market Determination

Made by: Nyrada Inc. ARBN 625 401 818 of Sydney Place, Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 Australia (**Company**)

Product: Attaching options to acquire fully-paid CHESS Depositary Interests in the Company (**CDIs**), offered under a prospectus dated 12 October 2026 (**Options**).

Effective date: 12 October 2026

This target market determination (**TMD**) has been prepared by the Company in relation to an offer to grant the Options made by the Company under a prospectus dated 12 October 2026 (**Prospectus**). **A copy of the Prospectus is available on the Company's website, <https://www.nyrada.com/site/content/>.**

The offer will be made under, or accompanied by, the Prospectus. Any recipient of this TMD should carefully read and consider the Prospectus in full and consult their professional adviser if they have any questions regarding the contents of the Prospectus.

There is no cooling-off period in respect of the grant of the Options.

This TMD is not a disclosure document for the purposes of the *Corporations Act 2001* (Cth) (**Corporations Act**), and therefore has not been lodged, and does not require lodgement, with the Australian Securities and Investments Commission (**ASIC**) nor does it contain a full summary of the terms and conditions of the Options.

This TMD does not take into account what you currently have, or what you want and need, for your financial future. It is important for you to consider these matters and read the Prospectus in full. The Company is not licensed to provide financial product advice in relation to the Options.

This TMD has been authorised for release by the Company's board of directors.

1. Product information

The key features of the Options are as follows:

Offer	The offer of Options to: • participants in the placement of CDIs by the Company to sophisticated and professional investors, raising approximately \$12,000,000 (before costs), the details of which were announced on the Australian Securities Exchange (ASX) on 21 September 2026 (Placement); and • successful applicants under the Nyrada Security Purchase Plan announced by the Company on ASX on 21 September 2026 (Security Purchase Plan),
--------------	--

	on the basis of three (3) Options for every four (4) CDIs issued under the Placement or the Security Purchase Plan (as applicable).
Eligibility	Participants in the Placement and successful applicants under the Security Purchase Plan (Eligible CDI Holders).
Issue Price	The Options are being issued for no additional consideration.
Entitlement to CDIs	Each Option entitles its holder to subscribe for one CDI upon exercise of the Option and payment of the exercise price prior to the expiry date.
Exercise Price	\$0.93
Expiry Date	25 September 2028
Exercise Period	The Options are exercisable at any time on or prior to the Expiry Date.
CDIs issued on exercise	CDIs issued on exercise of the Options will rank equally in all respects with the Company's existing fully paid CDIs on the date of issue.
Transferability	The Company will apply for official quotation of the Options on the ASX. The Options are transferrable prior to the expiry date, subject to any applicable restrictions on transfer under the ASX Listing Rules or applicable law.

The full terms and conditions of the Options are set out in section 5.1 of the Prospectus.

2. Target market

The below table summarises the overall class of consumers that fall within the target market for the Options, based on the Options' key attributes and the objectives, financial situation and needs that it has been designed to meet.

Investment Objective	The Company expects that an investment in Options will be suitable to investors seeking to have the right, but not the obligation, to gain exposure to equity in a clinical-stage biotechnology company listed on the ASX. Particularly, in relation to the Options offered under the Prospectus, it will be participants in the Placement and successful applicants under the Security Purchase Plan.
Investment Timeframe	The target market of investors will take a short to medium term outlook on their investment. Investors with a short-term outlook for their investment will benefit from an ability to transfer Options, or exercise Options and trade the underlying CDIs issued on exercise, should the exercise price of the Options be lower than the trading price of CDIs. Investors with a medium-term outlook will benefit from an ability to exercise the Options within the exercise period of the Options and increase their CDI holding and exposure to the potential upside in the Company's CDIs in the future. The Company will apply for official quotation of the Options on the ASX. The Options will be transferrable. Given the need to pay the exercise price in order to acquire CDIs, investors in the target market are in a financial position that is sufficient for them to invest their funds over the exercise period of the Options, should they wish to exercise their Options. Any decision to exercise the Options and sell the CDIs issued on

	exercise of the Options may be limited by a lack of liquidity in the CDIs and by the trading price of the underlying CDIs.
Investment Metrics	While the Company does not have an established eligibility framework for investors based on metrics such as age, expected return, or volatility, it is expected that the target market of investors will be able to withstand potential fluctuations in the value of their investment and will be accustomed to participating in speculative investments in the biotechnology sector. An exercise price is required to be paid to acquire CDIs on exercise of Options. As such, the capacity to realise the underlying value of the Options would require that they be exercised on or before the expiry date. Investors in the target market will need to be in a financial position to have sufficient available funds so as to facilitate an exercise of the Options prior to the expiry date. The Options are transferable. The Options offer no guaranteed income or capital protection.
Risk	Investors should consider that there is no guarantee that the Company's CDI price will exceed the exercise price of the Options. The Company considers that an investment in the Options is highly speculative, such that an investment in the Company is not appropriate for an investor who would not be able to bear a loss of some or all of the investment. Investors should also have a sufficient level of financial literacy and resources (either alone or in conjunction with an appropriate adviser) to understand and appreciate the risks of investing in Options as an asset class generally and the more specific risks of investing in a clinical-stage biotechnology company listed on the ASX. Specific risks relating to the Company and an investment in Options are set out in the Prospectus and investors should review those risks carefully.

3. **Distribution conditions**

The offer of the Options is made under the Prospectus to Eligible CDI Holders, being participants in the Placement and successful applicants under the Security Purchase Plan.

The Prospectus includes jurisdictional conditions on eligibility. The Company will also include on its web landing page for the offer of Options a copy of this TMD.

The Company considers that these distribution conditions will ensure that persons who are granted Options fall within the target market in circumstances where personal advice is not being provided to those persons by the Company.

4. **Review triggers**

The Options are being offered for a limited offer period set out in the Prospectus, after the conclusion of which the Options will no longer be available for investment by way of grant. It follows that the TMD will only apply in the period between the commencement of the offer of the Options and the grant of the Options (**Offer Period**) after which the TMD will be withdrawn.

To allow the Company to determine whether circumstances exist that indicate this TMD is no longer appropriate to the offer of the Options and should be reviewed, the following review triggers apply for the Offer Period:

- a) there is a material change to the Options' key attributes that makes them no longer consistent with the likely objectives, financial situation and needs of investors in the target market;
- b) the Company lodges with ASIC a supplementary or replacement prospectus in relation to the Prospectus;
- c) there is any event or circumstance that would materially change a factor taken into account in making this TMD;
- d) the existence of a significant dealing of the Options that is not consistent with this TMD;
- e) ASIC raises concerns with the Company regarding the adequacy of the design or distribution of the Options or this TMD; and
- f) material changes to the regulatory environment that applies to an investment in the Options.

5. Review

If a review trigger occurs during the Offer Period, the Company will undertake a review of the TMD in light of the review trigger (as applicable) as soon as reasonably practicable and, in any case, within 10 business days of the review trigger occurring.

The Company will otherwise complete a review of the TMD immediately prior to the grant of Options under the Offer.

6. Information reporting

The reporting requirements of all distributors are set out in the following table:

Reporting requirement	Period for reporting to the Company by the distributor	Information to be provided
Whether the distributor received complaints about the Options.	- For such time as the Offer Period remains open, within 10 business days after the end of each quarter. - Within 10 business days after the end of the Offer Period.	- The number of complaints received. - A summary of the nature of each complaint or a copy of each complaint.
A significant dealing of the Options that is not consistent with this TMD.	As soon as reasonably practicable after the significant dealing occurs, but in any event no later than 10 business days after the significant dealing occurs.	- Details of the significant dealing. - Reasons why the distributor considers that the significant dealing is not consistent with this TMD.

A summary of the steps taken by the distributor to ensure that its conduct was consistent with this TMD.	Within 10 business days after the close of the offer of Options in accordance with the Prospectus.	A summary of the steps taken by the distributor to ensure that its conduct was consistent with this TMD.
--	--	--

7. **Contact details**

Contact details in respect of this TMD for the Company are:

David Franks
Company Secretary
Phone: +61 2 8072 1400
Email: David.Franks@automicgroup.com.au